Comparing Empagliflozin and Sitagliptin for Managing High Blood Sugar in Hospitalized Patients
Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia: Randomised Control
This study is testing whether two diabetes medications, Empagliflozin and Sitagliptin, can help hospitalized patients manage their high blood sugar better than traditional insulin treatments.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 220 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medanta, The Medicity, India Academic / other |
| Locations | 1 site (Gurgaon, Haryana) |
| Trial ID | NCT06187285 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the efficacy and safety of two medications, Empagliflozin and Sitagliptin, in managing hyperglycemia in hospitalized patients with type 2 diabetes. The study aims to determine if these oral medications can provide better glycemic control compared to traditional insulin regimens, which are labor-intensive and carry a risk of hypoglycemia. Participants will include adults with type 2 diabetes who are admitted to general medicine or surgery and have specific blood glucose levels. The trial will assess the outcomes related to blood sugar management and overall clinical safety.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with type 2 diabetes and specific blood glucose levels who are admitted to general medicine or surgery.
Not a fit: Patients with type 1 diabetes, severe hyperglycemia, or those requiring intensive care may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could offer a safer and more convenient alternative for managing high blood sugar in hospitalized patients with type 2 diabetes.
How similar studies have performed: Previous studies have shown that oral medications like sitagliptin can be effective in hospitalized patients, suggesting potential for success with similar approaches.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients aged 18-years and above with type 2 diabetes and a random blood glucose concentration of 140-400 mg/dL who were being treated with diet or oral antidiabetic drugs or had a total daily insulin dose of 0•6 units per kg or less, admitted to general medicine or surgery Exclusion Criteria: Patients with a blood glucose concentration greater than 400mg/dL or with current or previous history of diabetic ketoacidosis, Type 1 diabetes, Hyperglycaemia without a known history of diabetes Patients expected to be without oral intake for more than 48 h Patients admitted to or expected to require admission to an intensive care unit Clinically relevant hepatic disease or impaired renal function \[eGFR\] \<30 mL/min per 1•73 m²) Pregnancy, and any mental health condition rendering the patient unable to give informed consent Current or recurrent uti(more than 2 times in last 6 months)
Where this trial is running
Gurgaon, Haryana
- Division Of Endocrinology & Diabetes, Medanta The Medicity — Gurgaon, Haryana, India (Recruiting)
Study contacts
- Study coordinator: Mr Surender, Msc
- Email: yadavsurender89@gmail.com
- Phone: 01244141414
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.